Fish oil and arthritis drug tested against aggressive breast cancer in young women

NCT ID NCT01881048

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested whether two anti-inflammatory drugs—fish oil (omega-3 fatty acid) and celecoxib (Celebrex)—could reduce inflammation and slow cancer growth in women aged 18-50 with pregnancy-associated breast cancer. The 42 participants took one of the drugs for at least a week before their planned surgery. The main goal was to measure changes in a tumor growth marker called Ki-67, gathering data to help design larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
omega-3 fatty acid (fish oil) and celecoxib
What this could lead to
If successful, this could point toward a way to reduce inflammation in pregnancy-associated breast cancer, potentially improving treatment options for this aggressive form of the disease.
What could go wrong
This is a very early, small study (42 participants) designed mainly to gather preliminary data, not to prove effectiveness. The results may not lead to a direct treatment, and the drugs may not show a meaningful effect on cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IA BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.